X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Update

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 9,480,000 shares, a decrease of 14.3% from the February 13th total of 11,060,000 shares. Approximately 5.7% of the company’s stock are sold short. Based on an average daily volume of 4,100,000 shares, the short-interest ratio is currently 2.3 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

Insider Buying and Selling

In other news, CFO Adam S. Mostafa sold 74,773 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Paula Ragan sold 76,473 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 202,663 shares of company stock valued at $91,198 over the last ninety days. Company insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Verition Fund Management LLC purchased a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth $30,000. Cantor Fitzgerald L. P. purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth $30,000. Atria Wealth Solutions Inc. purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth $44,000. Wells Fargo & Company MN lifted its holdings in shares of X4 Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after buying an additional 26,763 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after buying an additional 22,485 shares during the period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Price Performance

XFOR opened at $0.29 on Wednesday. The business has a fifty day moving average of $0.48 and a 200 day moving average of $0.54. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The stock has a market cap of $50.24 million, a P/E ratio of -3.27 and a beta of 0.39.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.